The experience of use of everolimus in patients having undergone to orthotopic liver transplantation

The efficacy and safety of everolimus in 10 recipients of liver in the post-transplant period with simultaneous reducing the dose of calcineurin inhibitors are analyzed. After conversion of immunosuppression the duration of monitoring of patients ranged from 4 to 18 months. Episodes of acute cellular rejection were not observed. Already in the first month after inclusion of everolimus in the scheme of immunosuppressive therapy, there was observed an improvement in renal function, which persisted at follow-up of patients. No serious adverse events were observed.